For instance, aromatase inhibitors can influence metabolic pathways, leading to hypertension, dyslipidemia, and insulin resistance, which are recognized risk factors for cardiovascular events.26,27 Lastly, for patients receiving radiation therapy, especially to the thorax, there is a well-documented risk of late cardiovascular complications due to radiation-induced damage to coronary arteries and the pericardium.28,29. Here, CYP19A1 is linked to metabolic syndrome.